<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210422083455+02'00'</creation_date><modification_date>D:20210422083455+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_48.pdf</pdf_file></head><body><section><header>en  
  en</header><p>european 
 commission</p><p>
 brussels, 21.4.2021</p><p>c(2021) 2940 final</p></section><section><header>commission implementing decision of 21.4.2021 
 withdrawing, at the holder&apos;s request, the marketing authorisation granted by decision 
 c(2000)1407 for &quot;pegintron - peginterferon alfa-2b&quot;, a medicinal product for human 
 use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decision of 21.4.2021 
 withdrawing, at the holder&apos;s request, the marketing authorisation granted by decision 
 c(2000)1407 for &quot;pegintron - peginterferon alfa-2b&quot;, a medicinal product for human 
 use</header><p>(text with eea relevance) (only the dutch text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, having regard to the application submitted by merck sharp &amp; dohme b.v. on 23 march 
 2021 with a view to the withdrawal of the marketing authorisation for the medicinal product 
 &quot;pegintron - peginterferon alfa-2b&quot;, 
 whereas: 
 (1) 
 the placing on the market of the medicinal product &quot;pegintron - peginterferon alfa-
 2b&quot;, which is entered in the union register of medicinal products under the number 
 eu/1/00/131 was authorised by commission decision c(2000)1407 of 25 may 2000. 
 (2) 
 following the holder&apos;s request, that authorisation should be withdrawn, 
 has adopted this decision: 
 article 1 at the holder&apos;s request, the marketing authorisation granted by decision c(2000)1407 of 25 may 2000 for the medicinal product &quot;pegintron - peginterferon alfa-2b&quot; is withdrawn.</p><p>
 1 oj l 136, 30.4.2004, p. 1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 2 this decision is addressed to merck sharp &amp; dohme b.v., waarderweg 39, 2031 bn haarlem, nederland. 
 done at brussels, 21.4.2021</p><p>for the commission</p><p>
 sandra gallina</p><p>
 director-general</p></section></body></xml>